Floatz logo

Opevesostat

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Merck Sharp & Dohme LLCSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

229 Active assets in the Metastatic Castration-resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Opevesostat is also rated in:

metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
B
Indicative ·
59 / 100
View asset →
cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →